Overview
Cerebrolysin REGistry Study in Stroke
Status:
Unknown status
Unknown status
Trial end date:
2020-12-01
2020-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ever Neuro Pharma GmbHCollaborator:
SITS InternationalTreatments:
Cerebrolysin
Criteria
Inclusion Criteria:- Signed informed consent
- Clinical diagnosis of acute ischemic stroke
- Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)
- Reasonable expectation of successful follow-up (max. 100 days)
Exclusion Criteria:
- none